Tuberculosis – Pipeline Review, H2 2019

“Global Markets Direct’s, ‘Tuberculosis – Pipeline Review, H2 2019’, provides an overview of the Tuberculosis pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Tuberculosis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Tuberculosis and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.”


– The report provides a snapshot of the global therapeutic landscape of Tuberculosis

– The report reviews pipeline therapeutics for Tuberculosis by companies and universities/research institutes based on information derived from company and industry-specific sources

– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

– The report reviews key players involved Tuberculosis therapeutics and enlists all their major and minor projects

– The report assesses Tuberculosis therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

– The report summarizes all the dormant and discontinued pipeline projects

– The report reviews latest news related to pipeline therapeutics for Tuberculosis”

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand important and diverse types of therapeutics under development for Tuberculosis

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Tuberculosis pipeline depth and focus of Indication therapeutics

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

“Abera Bioscience AB

AGILeBiotics BV

Akshaya Bio Inc

AN2 Therapeutics Inc

Archivel Farma SL

AstraZeneca Plc

Austrianni GmbH

BioLingus AG

BioNTech SE

Bioversys AG

CanSino Biologics Inc

Celgene Corp

Chongqing Zhifei Biological Products Co Ltd

Collaborations Pharmaceuticals Inc

Consegna Pharma Inc

Crestone Inc

Daiichi Sankyo Co Ltd

Demuris Ltd

Ebelle Pharmaceuticals Inc

Eisai Co Ltd

Eli Lilly and Co

Ena Therapeutics Pty Ltd

Enyo Pharma SA

EpiVax Inc

Evotec SE

Faron Pharmaceuticals Oy

Gamaleya Federal Research Center of Epidemiology and Microbiology

GangaGen Inc

GC Pharma

GlaxoSmithKline Plc

Globeimmune Inc

Greffex Inc

Guangdong Zhongsheng Pharmaceutical Co Ltd

HanaVax Inc

Hinova Pharmaceuticals Inc

Hsiri Therapeutics LLC

Immodulon Therapeutics Ltd

Immunitor Inc

ImmunoBiology Ltd

Innovare R & D SA De CV

ISR Immune System Regulation Holding AB

Johnson & Johnson

Kolmar Pharma Co Ltd

L2 Diagnostics LLC

LegoChem Biosciences Inc

Matinas BioPharma Holdings Inc

Merck & Co Inc

MetalloPharm LLC

Microbiotix Inc

Mycosynthetix Inc

Nearmedic Plus Ltd

Novartis AG

NovoBiotic Pharmaceuticals LLC


Opal Biosciences Ltd

Otsuka Holdings Co Ltd

Pai Life Sciences Inc

Palisades Therapeutics

Pathens Inc

Pfizer Inc


ProCrysta Biologix Inc

Q BioMed Inc

Qrumpharma Inc

Quratis Inc

QureTech Bio AB

Qurient Co Ltd


Sequella Inc

Serum Institute of India Ltd

Shanghai H&G Biotech

Shanghai Jiatan Pharmaceutical Technology Co Ltd

Shionogi & Co Ltd

Spero Therapeutics Inc

Sphaera Pharma Pte Ltd

Takeda Pharmaceutical Co Ltd

Target Medicals LLC


TenNor Therapeutics Ltd

The Broad Institute Inc

Theravectys SA

TVAX Biomedical Inc

Tydock Pharma Srl

Vaccibody AS

Vaxil Bio Therapeutics Ltd

Vaxinano SE

Vaxine Pty Ltd

Vichem Chemie Research Ltd

Vir Biotechnology Inc

Zata Pharmaceuticals Inc”

Table of Contents

Table of Contents

Table of Contents 2

Introduction 6

Tuberculosis - Overview 7

Tuberculosis - Therapeutics Development 8

Tuberculosis - Therapeutics Assessment 31

Tuberculosis - Companies Involved in Therapeutics Development 41

Tuberculosis - Drug Profiles 65

Tuberculosis - Dormant Projects 299

Tuberculosis - Discontinued Products 309

Tuberculosis - Product Development Milestones 310

Appendix 319

List of Tables

“List of Tables

Number of Products under Development for Tuberculosis, H2 2019

Number of Products under Development by Companies, H2 2019

Number of Products under Development by Universities/Institutes, H2 2019

Products under Development by Companies, H2 2019

Products under Development by Universities/Institutes, H2 2019

Number of Products by Stage and Target, H2 2019

Number of Products by Stage and Mechanism of Action, H2 2019

Number of Products by Stage and Route of Administration, H2 2019

Number of Products by Stage and Molecule Type, H2 2019

Tuberculosis – Pipeline by Abera Bioscience AB, H2 2019

Tuberculosis – Dormant Projects, H2 2019

Tuberculosis – Discontinued Products, H2 2019”


Discounts available for multiple report purchases.
+44 (0) 161 359 5414

Saved reports